CN115666584A - 用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法 - Google Patents

用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法 Download PDF

Info

Publication number
CN115666584A
CN115666584A CN202180038537.5A CN202180038537A CN115666584A CN 115666584 A CN115666584 A CN 115666584A CN 202180038537 A CN202180038537 A CN 202180038537A CN 115666584 A CN115666584 A CN 115666584A
Authority
CN
China
Prior art keywords
inhibitor
cancer
selectin
individual
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038537.5A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·L·麦格纳尼
威廉·E·福格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CN115666584A publication Critical patent/CN115666584A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180038537.5A 2020-05-31 2021-05-28 用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法 Pending CN115666584A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063032675P 2020-05-31 2020-05-31
US63/032,675 2020-05-31
US202063060595P 2020-08-03 2020-08-03
US63/060,595 2020-08-03
US202063063892P 2020-08-10 2020-08-10
US63/063,892 2020-08-10
US202063198864P 2020-11-18 2020-11-18
US63/198,864 2020-11-18
PCT/US2021/034773 WO2021247396A1 (en) 2020-05-31 2021-05-28 Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis

Publications (1)

Publication Number Publication Date
CN115666584A true CN115666584A (zh) 2023-01-31

Family

ID=76624176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038537.5A Pending CN115666584A (zh) 2020-05-31 2021-05-28 用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法

Country Status (5)

Country Link
US (1) US20230165882A1 (enExample)
EP (1) EP4157285A1 (enExample)
JP (1) JP2023527411A (enExample)
CN (1) CN115666584A (enExample)
WO (1) WO2021247396A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063768A1 (en) * 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
WO2018031445A1 (en) * 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
AU2008336249B2 (en) 2007-12-10 2015-01-29 The University Of Queensland Treatment and prophylaxis
AU2010241807B2 (en) 2009-05-01 2014-08-14 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
EP2794626B3 (en) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
EP3383882A1 (en) 2015-12-02 2018-10-10 GlycoMimetics, Inc. Heterobifunctional pan-selectin antagonists having a triazole linker
BR112019006642A2 (pt) 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3136661A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
US20220220144A1 (en) 2019-04-24 2022-07-14 Glycomimetics, Inc. Multimeric pan-selectin antagonists
CN114341368A (zh) 2019-07-12 2022-04-12 糖模拟物有限公司 使用基因表达作为多种肿瘤类型的e-选择素抑制剂功效和临床结果的指标的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063768A1 (en) * 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
WO2018031445A1 (en) * 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4

Also Published As

Publication number Publication date
US20230165882A1 (en) 2023-06-01
WO2021247396A1 (en) 2021-12-09
EP4157285A1 (en) 2023-04-05
JP2023527411A (ja) 2023-06-28

Similar Documents

Publication Publication Date Title
Pillozzi et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers
Mercurio et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
Mueller et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer
CN117794929A (zh) 选择性bcl-xl protac化合物及使用方法
JP2023024618A (ja) がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
Recasens-Zorzo et al. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma
Du et al. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)
Dolgova et al. Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma
KR20190032425A (ko) 질환 치료에서의 gzd824 및 이의 약학적으로 허용가능한 염의 신규 용도
KR20240041917A (ko) 암의 치료 및/또는 예방을 위한 의약품
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
CN116033907A (zh) 经由e-选择素靶向克服微环境介导的抗性的组合物和方法
US20230165882A1 (en) Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
JP2019525924A (ja) がんを処置するための併用療法
US10550130B2 (en) Benzo-thiazolo-imidazole compounds and uses thereof
TWI867142B (zh) 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
KR20250054778A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN112007164B (zh) 降低tcrp1的表达或活性的试剂在制备增强石蒜碱的抗肝癌活性药物中的应用
US20210161851A1 (en) Combination therapy of lymphoma
HK40025641B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
KR20250052368A (ko) 암의 치료 및/또는 예방을 위한 의약품
HK40106158A (en) Combination mcl-1 inhibitors with anti-body drug conjugates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230131